Abstract

There in an increase in demand for reliable, inexpensive and rapid drug susceptibility assay because of expanding anti-tuberculosis drug-resistant Mycobacterium tuberculosis necessitating the need for appropriate treatment. One of the major challenges being faced is the lack of resources and the limiting of reliable drug susceptibility test meeting acceptable levels only for isoniazid and rifampicin. In this article, an overview of different drug susceptibility testing and assays is detailed and the advantages and disadvantages highlighted. It discusses the perspective on conventional methods which have paved the way for modern DSTs along with the advancements made in the conventional methods.

Keywords: Drug Susceptibility; Anti-tuberculosis; Mycobacterium tuberculosis; Conventional DST’s

References

1. Chakravorty S., et al. “Genotypic susceptibility testing of Mycobacterium tuberculosis isolates for amikacin and kanamycin resistance by use of a rapid sloppy molecular beacon-based assay identifies more cases of low-level drug resistance than phenotypic Lowenstein-Jensen testin”. Journal of Clinical Microbiology1 (2015): 43-51.
2. World health organization (WHO). “Global tuberculosis report 2019” (2019).
3. Kim K., et al. “A low cost/low power open source sensor system for automated tuberculosis drug susceptibility testing”. Sensors (Switzerland) 16.6 (2016).
4. Campbell PJ., et al. “Molecular Detection of Mutations Associated with First-and Second-Line Drug Resistance Compared with Conventional Drug Susceptibility Testing of Mycobacterium tuberculosis † §”. Antimicrobial Agents and Chemotherapy5 (2011): 2032-2041.
5. Kim SJ. “Controversial Issues in Tuberculosis” (2004).
6. Diriba G., et al. “Performance of Mycobacterium Growth Indicator Tube BACTEC 960 with Lowenstein-Jensen method for diagnosis of Mycobacterium tuberculosis at Ethiopian National Tuberculosis Reference Laboratory, Addis Ababa, Ethiopia”. BMC Research Notes1 (2017).
7. Boum Y., et al. “Use of colorimetric culture methods for detection of Mycobacterium tuberculosis complex isolates from sputum samples in resource-limited settings”. Journal of Clinical Microbiology7 (2013): 2273-2279.
8. Martin A., et al. “Multicentre laboratory validation of the colorimetric redox indicator (CRI) assay for the rapid detection of extensively drug-resistant (XDR) Mycobacterium tuberculosis”. Journal of Antimicrobial Chemotherapy4 (2011): 827-833.
9. Riska PF., et al. “Rapid film-based determination of antibiotic susceptibilities of Mycobacterium tuberculosis strains by using a luciferase reporter phage and the Bronx Box”. Journal of Clinical Microbiology 4 (1999): 1144-1149.
10. Martin A., et al. “Colorimetric redox-indicator methods for the rapid detection of multidrug resistance in Mycobacterium tuberculosis: A systematic review and meta-analysis”. Journal of Antimicrobial Chemotherapy2 (2007): 175-183.
11. Canetti G., et al. “Mycobacteria: Laboratory Methods for Testing Drug Sensitivity and Resistance” (1963).
12. van Klingeren, B., et al. “Drug Susceptibility Testing of Mycobacterium tuberculosis Complex by Use of a High-Throughput, Reproducible, Absolute Concentration Method”. Journal of Clinical Microbiology8 (2007): 2662-2668.
13. World health organization (WHO). Guidelines for surveillance of drug resistance in tuberculosis 5^th Edition (2015).
14. Acharya S., et al. “Comparison of Proportion and Resistance Ratio Methods for Drug Susceptibility Testing of Mycobacterium tuberculosis Isolated from Patients Attending National Tuberculosis Centre, Nepal”. SAARC Journal of Tuberculosis, Lung Diseases and HIV/AIDS1 (2010): 13-20.
15. Jhamb SS., et al. “Determination of the activity of standard anti-tuberculosis drugs against intramacrophage Mycobacterium tuberculosis, in vitro: MGIT 960 as a viable alternative for BACTEC 460”. Brazilian Journal of Infectious Diseases3 (2014): 336-340.
16. Huang TS., et al. “Antimicrobial susceptibility testing of Mycobacterium tuberculosis to first-line drugs: comparisons of the MGIT 960 and BACTEC 460 systems”. Annals of Clinical and Laboratory Science2 (2002): 142-147.
17. Bemer P., et al. “Multicenter evaluation of fully automated BACTEC mycobacteria growth indicator tube 960 system for susceptibility testing of Mycobacterium tuberculosis”. Journal of Clinical Microbiology1 (2002): 150-154.
18. Yajko DM., et al. “Colorimetric Method for Determining MICs of Antimicrobial Agents for Mycobacterium tuberculosis”. Journal of Clinical Microbiology (1995).
19. Martin A., et al. “Colorimetric redox-indicator methods for the rapid detection of multidrug resistance in Mycobacterium tuberculosis: A systematic review and meta-analysis”. Journal of Antimicrobial Chemotherapy2 (2007): 175-183.
20. Katawera V., et al. “Evaluation of the modified colorimetric resazurin microtiter plate-based antibacterial assay for rapid and reliable tuberculosis drug susceptibility testing”. BMC Microbiology1 (2014): 259.
21. Bwanga F., et al. “Direct susceptibility testing for multi drug resistant tuberculosis: A meta-analysis”. BMC Infectious Diseases1 (2009): 67.
22. Syre H., et al. “Rapid Colorimetric Method for Testing Susceptibility of Mycobacterium tuberculosis to Isoniazid and Rifampin in Liquid Cultures”. Journal of Clinical Microbiology11 (2003): 5173-5177.
23. Kam KM. “Microscopic observation drug susceptibility (mods): Where are we going?” International Journal of Tuberculosis and Lung Disease2 (2014): 127.
24. Wang L., et al. “Evaluating the Auto-MODS Assay, a Novel Tool for Tuberculosis Diagnosis for Use in Resource-Limited Settings” (2015).
25. Line probe assays for drug-resistant tuberculosis detection Interpretation and reporting guide for laboratory staff and clinicians. (n.d.).
26. Automated Real-Time Nucleic Acid Amplification Technology for Rapid and Simultaneous Detection of Tuberculosis and Rifampicin Resistance: Xpert MTB/RIF Assay for the Diagnosis of Pulmonary and Extrapulmonary TB in Adults and Children: Policy update. World Health Organisation (2013): 1-79.
27. Helb D., et al. “Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology”. Journal of Clinical Microbiology1 (2010): 229-237.
28. Raja S., et al. “Technology for Automated, Rapid, and Quantitative PCR or Reverse Transcription-PCR Clinical Testing”. Clinical Chemistry5 (2005): 882-890.
29. Boehme CC., et al. “Rapid molecular detection of tuberculosis and rifampin resistance”. The New England Journal of Medicine11 (2010): 1005-1015.
30. National Center for HIV., et al. “A New Tool to Diagnose Tuberculosis: The Xpert MTB/RIF Assay What is the Xpert MTB/RIF Assay? How Does the Xpert MTB/RIF Assay Work?”.
31. Gu Y., et al. “Xpert MTB/RIF and GenoType MTBDRplus assays for the rapid diagnosis of bone and joint tuberculosis”. International Journal of Infectious Diseases 36 (2015): 27-30.
32. Rice JE., et al. “Fluorescent signatures for variable DNA sequences”. Nucleic Acids Research21 (2012): e164-e164.
33. Nguyen TNA., et al. “Molecular Diagnosis of Drug-Resistant Tuberculosis; A Literature Review.” Frontiers in Microbiology 10 (2019): 794.
34. FluoroType^® MTBDR | Detection of tuberculosis and its resistances. (n.d.).
35. Dheda K., et al. “The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis”. The Lancet Respiratory Medicine 4 (2017): 291-360.
36. Phelan J., et al. “The variability and reproducibility of whole genome sequencing technology for detecting resistance to anti-tuberculous drugs”. Genome Medicine 1 (2016): 132.
37. Daum LT., et al. “Next-generation ion torrent sequencing of drug resistance mutations in Mycobacterium tuberculosis strains”. Journal of Clinical Microbiology12 (2012): 3831-3837.
38. Genestet C., et al. “Whole-genome sequencing in drug susceptibility testing of Mycobacterium tuberculosis in routine practice in Lyon, France”. International Journal of Antimicrobial Agents (2020): 105912.
39. Quan TP., et al. “Evaluation of Whole-Genome Sequencing for Mycobacterial Species Identification and Drug Susceptibility Testing in a Clinical Setting: a Large-Scale Prospective Assessment of Performance against Line Probe Assays and Phenotyping”. Journal of Clinical Microbiology 2 (2018).
40. Zignol M., et al. “Genetic sequencing for surveillance of drug resistance in tuberculosis in highly endemic countries: a multi-country population-based surveillance study”. The Lancet Infectious Diseases 6 (2018): 675-683.
41. Galí N., et al. “Use of a mycobacteriophage-based assay for rapid assessment of susceptibilities of Mycobacterium tuberculosis isolates to isoniazid and influence of resistance level on assay performance”. Journal of Clinical Microbiology1 (2006): 201-205.
42. DeRisi Joseph., et al. “β-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer's therapy”. Nature 4 (1996): 822-826.
43. Eltringham IJ., et al. “Evaluation of a bacteriophage-based assay (phage amplified biologically assay) as a rapid screen for resistance to isoniazid, ethambutol, streptomycin, pyrazinamide, and ciprofloxacin among clinical isolates of Mycobacterium tuberculosis”. Journal of Clinical Microbiology11 (1999): 3528-3532.
44. Khan ZA., et al. “Current and emerging methods of antibiotic susceptibility testing”. Diagnostics 9 (2019).
45. Kim SJ. “Drug-susceptibility testing in tuberculosis: Methods and reliability of results”. European Respiratory Journal3 (2005): 564-569.
46. Molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (mdr-tb) policy statement (2008).
47. Siddiqi SH. Becton Dickinson Diagnostic Instruments System. Maryland, USA. BACTEC TB system. Product and procedure manual (1996).

Citation

Citation: Vikas Jha., et al. “An Overview of the Drug Susceptibility Testing for Tuberculosis". Acta Scientific Microbiology 3.8 (2020): 47-56.

Copyright

Copyright: © 2020 Vikas Jha., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.